Frank Landolt
V.P. IP and Legal
Ablynx N.V

Frank Landolt heads the IP and legal department within Ablynx, a listed biopharmaceutical company based in Ghent, Belgium with currently more than 300 staff, 6 products in clinical development and an IP portfolio of more than 500 patent applications and patents.

After studying chemistry and law at the University of Leiden in the Netherlands, Frank worked for almost ten years on pharmaceutical and biotechological patents and licensing in private practice in the Netherlands, where his clients included major pharmaceutical companies as well as some of the top biotech firms and research institutions in the Netherlands.

Prior to joining Ablynx as IP and legal counsel in 2004, Frank worked for four years as director of IP and legal counsel at Devgen N.V., another Ghent-based biotechnology company, where he was involved in negotiating the strategic collaborations with Sumitomo, Monsanto and DuPont Pioneer.

At Ablynx, where he heads an integrated IP and legal group of 4 patent attorneys and 3 lawyers, Frank has been involved in negotiating Ablynx’s strategic partnerships and licensing deals with AbbVie, MSD, Boehringer-Ingelheim, Merck-Serono, MSD, Novartis and Wyeth.

Frank is a Dutch and European patent attorney, and also holds a degree in business law from the University of Antwerp. He is a member of the Dutch association of patent attorneys (where he is a tutor for the professional qualification course), EPI, LES Benelux (where he is involved in the LES Licensing Course) and l’Institute des Juristes d’Enterprises. He is a regular speaker on a range of topics relating to IP and licensing in the (bio)pharmaceutical sector.